RxDoctor Payments Data

Caryel Kruger

Family · Beeville, TXNPI 1790010270

Payments from drug & device makers

$6,932in general payments, 2019–2025

Across 390 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$733
  • Merck$514
  • Boehringer Ingelheim$491
  • Amgen$368
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$6,83699%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,932 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$83,842
JardianceEmpagliflozin58$63,886
TrulicityDulaglutide44$55,226
MounjaroTirzepatide42$44,424
EliquisApixaban51$39,087
ProliaDenosumab16$27,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$22,890
LinzessLinaclotide39$21,367
FarxigaDapagliflozin Propanediol30$20,528
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$18,208
EntrestoSacubitril/Valsartan28$17,106
MyrbetriqMirabegron28$16,058
VascepaIcosapent Ethyl33$13,661
XareltoRivaroxaban20$13,478
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$733$99,65186 claims
Novo NordiskOzempic$1,092$83,84286 claims
Boehringer IngelheimJardiance, Synjardy Xr$491$71,20771 claims
PfizerEliquis$72$39,08751 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,474$37,81962 claims
AmgenProlia$368$27,46616 claims
GSKTrelegy Ellipta$325$22,89022 claims
AbbVieLinzess, Armour Thyroid$178$22,15763 claims
NovartisEntresto$78$17,10628 claims
Astellas Pharma US IncMyrbetriq$215$16,05828 claims
Johnson & JohnsonXarelto$170$13,47820 claims
MerckJanumet Xr$514$11,21713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Beeville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →